Skip to Content
Merck

A1774

Amikacin disulfate salt

potency: 674-786 μg per mg (as amikacin base)

Synonym(s):

(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide disulfate, Antibiotic BB-K8 sulfate

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

250 MG

748,00 kr.

1 G

2.380,00 kr.

5 G

8.660,00 kr.

748,00 kr.

Please contact Customer Service for Availability
Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C22H43N5O13 · 2H2SO4
CAS Number:
39831-55-5
Molecular Weight:
781.76
UNSPSC Code:
51281632
NACRES:
NA.85
PubChem Substance ID:
24890586
EC Number:
254-648-6
Beilstein/REAXYS Number:
6172633
MDL number:
MFCD00167475

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Amikacin disulfate salt, potency: 674-786 μg per mg (as amikacin base)

InChI key

FXKSEJFHKVNEFI-GCZBSULCSA-N

InChI

1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1

SMILES string

OS(O)(=O)=O.OS(O)(=O)=O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

biological source

synthetic

form

powder or crystals

potency

674-786 μg per mg (as amikacin base)

color

white to off-white

antibiotic activity spectrum

Gram-negative bacteria
mycobacteria

mode of action

protein synthesis | interferes

storage temp.

2-8°C

Quality Level

200

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
A2324K1876A3650
Amikacin disulfate salt potency: 674-786 μg per mg (as amikacin base)

Sigma-Aldrich

A1774

Amikacin disulfate salt

Amikacin sulfate salt aminoglycoside antibiotic

Sigma-Aldrich

A2324

Amikacin sulfate salt

Kanamycin disulfate salt from Streptomyces kanamyceticus aminoglycoside antibiotic

Sigma-Aldrich

K1876

Kanamycin disulfate salt from Streptomyces kanamyceticus

Amikacin hydrate aminoglycoside antibiotic

Sigma-Aldrich

A3650

Amikacin hydrate

mode of action

protein synthesis | interferes

mode of action

protein synthesis | interferes

mode of action

protein synthesis | interferes

mode of action

protein synthesis | interferes

antibiotic activity spectrum

Gram-negative bacteria, mycobacteria

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria, mycobacteria

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria, mycobacteria, mycoplasma

antibiotic activity spectrum

Gram-negative bacteria, mycobacteria

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

200

form

powder or crystals

form

powder

form

powder

form

powder

potency

674-786 μg per mg (as amikacin base)

potency

-

potency

~650 μg per mg

potency

-

biological source

synthetic

biological source

synthetic

biological source

Streptomyces kanamyceticus

biological source

synthetic

Application

Amikacin is an aminoglycoside antibiotic commonly used in the treatment of drug-resistant mycobacteria [1]. It is used to study organism-directed delivery of antibiotics as well as drug resistance [2].

Biochem/physiol Actions

Amikacin prevents bacterial protein synthesis by binding to the 30S ribosome subunit and inducing mRNA misreading.

General description

Chemical structure: aminoglycoside

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Warning

Hazard Classifications

Repr. 2 - Skin Sens. 1

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000504466
0000504466
0000509260
0000509260
0000426449

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A M Lovering et al.
The Journal of antimicrobial chemotherapy, 43(5), 719-721 (1999-06-26)
Antibiotic-free human serum was spiked with known concentrations of liposomal amikacin and assayed on the Abbott TDx System, using polarization fluoroimmuno assay (PFIA) kits from Abbott Laboratories, Oxis and Sigma. Although all three kits gave a linear response, the Abbott
Targeted Delivery of Amikacin into Granuloma.
Ana Montes-Worboys, et al.
American Journal of Respiratory Cell and Molecular Biology, 182, 1546-1553 (2010)
Kathryn Y Burge et al.
Journal of human lactation : official journal of International Lactation Consultant Association, 35(3), 538-549 (2019-05-06)
Human milk is known to be protective against necrotizing enterocolitis, a devastating intestinal inflammatory disease affecting the preterm population. Although the pathogenesis of necrotizing enterocolitis is yet to be solidified, intestinal integrity dysfunction, bacterial invasion and/or translocation, and inflammation may
Dorota Wrześniok et al.
Toxicology in vitro : an international journal published in association with BIBRA, 27(3), 1102-1108 (2013-02-19)
Amikacin is principally used to treat infections caused by microorganisms resistant to other aminoglycosides. Ototoxicity is one of the side effects of amikacin, but the causative mechanism of damage to the ear has not been fully established. Thus, the aim
Anna Belcarz et al.
International journal of pharmaceutics, 454(1), 285-295 (2013-07-16)
Following the quest for new composite materials for bone tissue engineering, a novel elastic hydroxyapatite-glucan composite loaded with two aminoglycoside antibiotics was prepared. The porosity of the composite and the drug release profiles in closed-loop and semi-open systems were tested.
View All Related Papers

Related Content

Product Information Sheet - A1774

Product Information Sheet

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service